Shorts:
- Pfizer will acquire all outstanding shares of Trillium for $18.50/share in cash making a total equity value of $2.26B with 203.8% premium on the stock’s last closing price
- The acquisition will bolster Pfizer’s R&D capabilities & accelerates clinical development of Trillium’s SIRPα fusion proteins i.e., TTI-622 & TTI-621 that are currently in P-Ib/II trial for hematological malignancies
- In clinical studies, TTI-622 & TTI-621 demonstrated the activity as monothx. in r/r lymphoid malignancies, including DLBCL, PTCL, FL, & other lymphoid malignancies. Additionally, Trillium’s biologics treatments will enhance patients innate immune systems to detect & destroy cancer cells
Click here to read full press release/ article | Ref: Businesswire | Image: Trillium
The post Pfizer to Acquire Trillium for ~$2.26B first appeared on PharmaShots.
